24h250

200

% Viability

150

150

100

E

MiaPaCa2

100

A

HPDE

\* \*\*

% Viability

50

50

0 0

48h150

B

\*

\*\*\*\*

100

% Viability

50

0

Dose CE (g/mL)

150

100

% Viability

50

0

Dose CE (g/mL)

|  |
| --- |
| FGI50 = 1475 g/mL |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \*\*\*\* \*\*\*\* |
|  |  |
|  |  |  |

### 72h

150

100

% Viability

Dose CE (g/mL)

150

100

Dose CE (g/mL)

L

|  |
| --- |
| GGI50 = 711.6 g/m |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | \*\*\*\* \*\*\*\* |

50 50

C

\*

\*

\*\*\*\*

% Viability

0 0

96h150

D

\*\*\*\*

Dose CE (g/mL)

150

Dose CE (g/mL)

100 100

H

GI50 = 821.8 g/mL

\*\*\*\* \*\*\*\*

% Viability

% Viability

50 50

0 0

Supplementary Figure 1 Viability of HPDE and MiaPaCa2 cells treated with CE ranging from 0-1000 µg/mL and Gemcitabine 50nM determined by CCK 8 colourimetric assay. *HPDE cells treated with CE for A: 24 hours, B: 48 hours, C: 72 hours, D: 96 hours; MiaPaCa2 cells treated with CE for E: 24 hours F: 48 hours (GI50 1475 µg/mL), G: 72 hours (GI50 711.6 µg/mL), H: 96 hours (GI50 821.8 µg/mL). Significance between treatment groups and the negative control calculated using one-way ANOVA represented over treatment columns by ‘\*’ = p<0.05, ‘\*\*’ = p<0.01, ‘\*\*\*’ = p<0.005, ‘\*\*\*\*’ = p<0.001.*